2 research outputs found
Coronary CT Angiography and 5-Year Risk of Myocardial Infarction.
BACKGROUND: Although coronary computed tomographic angiography (CTA) improves diagnostic certainty in the assessment of patients with stable chest pain, its effect on 5-year clinical outcomes is unknown. METHODS: In an open-label, multicenter, parallel-group trial, we randomly assigned 4146 patients with stable chest pain who had been referred to a cardiology clinic for evaluation to standard care plus CTA (2073 patients) or to standard care alone (2073 patients). Investigations, treatments, and clinical outcomes were assessed over 3 to 7 years of follow-up. The primary end point was death from coronary heart disease or nonfatal myocardial infarction at 5 years. RESULTS: The median duration of follow-up was 4.8 years, which yielded 20,254 patient-years of follow-up. The 5-year rate of the primary end point was lower in the CTA group than in the standard-care group (2.3% [48 patients] vs. 3.9% [81 patients]; hazard ratio, 0.59; 95% confidence interval [CI], 0.41 to 0.84; P=0.004). Although the rates of invasive coronary angiography and coronary revascularization were higher in the CTA group than in the standard-care group in the first few months of follow-up, overall rates were similar at 5 years: invasive coronary angiography was performed in 491 patients in the CTA group and in 502 patients in the standard-care group (hazard ratio, 1.00; 95% CI, 0.88 to 1.13), and coronary revascularization was performed in 279 patients in the CTA group and in 267 in the standard-care group (hazard ratio, 1.07; 95% CI, 0.91 to 1.27). However, more preventive therapies were initiated in patients in the CTA group (odds ratio, 1.40; 95% CI, 1.19 to 1.65), as were more antianginal therapies (odds ratio, 1.27; 95% CI, 1.05 to 1.54). There were no significant between-group differences in the rates of cardiovascular or noncardiovascular deaths or deaths from any cause. CONCLUSIONS: In this trial, the use of CTA in addition to standard care in patients with stable chest pain resulted in a significantly lower rate of death from coronary heart disease or nonfatal myocardial infarction at 5 years than standard care alone, without resulting in a significantly higher rate of coronary angiography or coronary revascularization. (Funded by the Scottish Government Chief Scientist Office and others; SCOT-HEART ClinicalTrials.gov number, NCT01149590 .)
CT coronary angiography in patients with suspected angina due to coronary heart disease (SCOT-HEART): an open-label,parallel-group, multicentre trial
Background The benefi t of CT coronary angiography (CTCA) in patients presenting with stable chest pain has not
been systematically studied. We aimed to assess the eff ect of CTCA on the diagnosis, management, and outcome of
patients referred to the cardiology clinic with suspected angina due to coronary heart disease.
Methods In this prospective open-label, parallel-group, multicentre trial, we recruited patients aged 18–75 years referred
for the assessment of suspected angina due to coronary heart disease from 12 cardiology chest pain clinics across
Scotland. We randomly assigned (1:1) participants to standard care plus CTCA or standard care alone. Randomisation
was done with a web-based service to ensure allocation concealment. The primary endpoint was certainty of the diagnosis
of angina secondary to coronary heart disease at 6 weeks. All analyses were intention to treat, and patients were analysed
in the group they were allocated to, irrespective of compliance with scanning. This study is registered with
ClinicalTrials.gov, number NCT01149590.
Findings Between Nov 18, 2010, and Sept 24, 2014, we randomly assigned 4146 (42%) of 9849 patients who had been
referred for assessment of suspected angina due to coronary heart disease. 47% of participants had a baseline clinic
diagnosis of coronary heart disease and 36% had angina due to coronary heart disease. At 6 weeks, CTCA reclassifi ed
the diagnosis of coronary heart disease in 558 (27%) patients and the diagnosis of angina due to coronary heart
disease in 481 (23%) patients (standard care 22 [1%] and 23 [1%]; p<0·0001). Although both the certainty (relative risk
[RR] 2·56, 95% CI 2·33–2·79; p<0·0001) and frequency of coronary heart disease increased (1·09, 1·02–1·17;
p=0·0172), the certainty increased (1·79, 1·62–1·96; p<0·0001) and frequency seemed to decrease (0·93, 0·85–1·02;
p=0·1289) for the diagnosis of angina due to coronary heart disease. This changed planned investigations (15% vs 1%;
p<0·0001) and treatments (23% vs 5%; p<0·0001) but did not aff ect 6-week symptom severity or subsequent
admittances to hospital for chest pain. After 1·7 years, CTCA was associated with a 38% reduction in fatal and nonfatal
myocardial infarction (26 vs 42, HR 0·62, 95% CI 0·38–1·01; p=0·0527), but this was not signifi cant.
Interpretation In patients with suspected angina due to coronary heart disease, CTCA clarifi es the diagnosis, enables
targeting of interventions, and might reduce the future risk of myocardial infarction.
Funding The Chief Scientist Offi ce of the Scottish Government Health and Social Care Directorates funded the trial
with supplementary awards from Edinburgh and Lothian’s Health Foundation Trust and the Heart Diseases
Research Fund